Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC) Pilot Study
The Rapid-EC pilot study will determine feasibility of providing rapid point-of-care (POC) testing for HCV in community clinics, and whether the availability of POC testing increases uptake of testing, engagement in care and…
- Trial name
- NCT03231930
- Testing
- OraQuick HCV Ab test, Xpert HCV viral load test
- Where
- 3 sites in Australia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis C, Chronic, Substance Use Disorders
Linkage to Care for Persons With Hep C Infection
Hepatitis C Virus (HCV) infection is an ongoing challenge in the United States, with an estimated 2.4 million individuals living with HCV in 2016.
- Trial name
- NCT05397067
- Testing
- Peer specialist (PS), Incentives, telehealth visits
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Carilion Clinic
Viral Hepatitis C, HIV
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
Aim of the study is to assess the efficacy and safety of 24 weeks of oral Sofosbuvir/Ledipasvir fixed-dose combination (FDC) in subjects with HCV genotype 1 infection and HIV co-infection, who have previously failed a NS3/4A…
- Trial name
- NCT02125500
- Testing
- Sofosbuvir/Ledipasvir fixed dose
- Where
- France
- Volunteers
- 68 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Viral Hepatitis C
Re-linkage to Care of Patients With Hepatitis C
The purpose of this study is to identify patients with chronic hepatitis C virus (HCV) who were lost of follow up and relinkage them to hepatitis C care
- Trial name
- NCT04470271
- Testing
- Patients with hepatitis C lost follow up
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- Austral University, Argentina
Chronic Hepatitis C (CHC)
A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)
This is a study designed to compare the safety and efficacy of 3 different doses of grazoprevir (MK-5172) combined with pegylated interferon alfa-2b (PEG-IFN) and ribavirin (RBV) in treatment-naïve participants with genotype 1…
- Trial name
- NCT01710501
- Testing
- Grazoprevir, pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 87 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382
The purpose of this study is to investigate the safety, tolerability and plasma pharmacokinetics (PK) of JNJ-47910382 after increasing single oral doses (taken with food) from 10 mg up to 600 mg or up to the maximum tolerated…
- Trial name
- NCT01482611
- Testing
- JNJ-47910382
- Where
- Germany
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Janssen R&D Ireland
Hepatitis C
Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)
The purpose of this observational study was to provide summary data from participants who relapsed at the end of the follow-up phase after 24 weeks of treatment with standard care PegIntron plus ribavirin in Part 1 of the study…
- Trial name
- NCT01054742
- Testing
- Standard of Care PegIntron, Standard of Care Ribavirin
- Volunteers
- 2 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV…
- Trial name
- VALOR-HCV (NCT02128542)
- Testing
- Sofosbuvir, RBV
- Where
- 17 sites in United States
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects
A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated.
- Trial name
- NCT02112942
- Testing
- IDX21459
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects…
- Trial name
- ION-2 (NCT01768286)
- Testing
- LDV/SOF, RBV
- Where
- 53 sites in United States
- Volunteers
- 441 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to…
- Trial name
- ACTIVATE (NCT01364090)
- Testing
- Pegylated interferon alfa 2b, Ribavirin
- Where
- 17 sites in Australia, Belgium and 5 more
- Volunteers
- 93 people
- Sponsor
- Kirby Institute
Chronic Hepatitis, C Virus
Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.
The purpose of this study is to determinate the AMH levels before and after antiviral therapy with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched HCV-positive women not undergoing antiviral…
- Trial name
- NCT02950870
- Testing
- Ombitasvir-Paritaprevir-Ritonavir, Dasabuvir, Ribavirin
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- University of Modena and Reggio Emilia
Hepatitis C, Chronic
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons.
- Trial name
- NCT01054573
- Testing
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 90 people
- Sponsor
- Janssen Infectious Diseases BVBA
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
The purpose of this Phase 2, open-label, 2-part, multicenter study was to evaluate the efficacy, safety, and pharmacokinetics of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) at different doses in…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV
- Trial name
- NCT02243280
- Testing
- ABT-493, ABT-530
- Volunteers
- 174 people
- Sponsor
- AbbVie
Hepatitis C
Study of a Novel Therapeutic Vaccine for Hepatitis C Virus
HCV002TV is a Phase I study to ascertain the safety and immunogenicity of a novel vaccine against Hepatitis C virus (HCV) in chronically infected patients.
- Trial name
- NCT01094873
- Testing
- AdCh3NSmut, Ad6NSmut
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- ReiThera Srl
Hepatitis C
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received…
- Trial name
- NCT01446250
- Testing
- Alisporivir, Boceprevir, Peginterferon alfa-2a
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Debiopharm International SA
Hepatitis
Hepatitis C: Grading and Staging by MR
To compare MR imaging findings with biopsy for grading and staging early hepatitis C.
- Trial name
- NCT00059397
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV, HIV Infections
Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression.
- Trial name
- NCT00358696
- Testing
- tenofovir
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Thrombocytopenia
Managed Access Programs for ETB115, Eltrombopag
The purpose of this registration is to list Managed Access Programs (MAPs) related to ETB115, Eltrombopag
- Trial name
- NCT04837703
- Testing
- Eltrombopag
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic, Cirrhosis
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2.
- Trial name
- NCT02113631
- Testing
- Telaprevir, Boceprevir, Peg-IFN
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Louis Stokes VA Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.